New study in The Oncologist supports the use of blood-based tumor DNA (liquid biopsies) in hepatocellular carcinoma (HCC) to facilitate personalized medicine. The CureMatch decision support platform matches personalized drug combinations for liver cancer patients. SAN DIEGO, CA – March 26, 2018: A new cancer study reports that next-generation sequencing of circulating tumor DNA (ctDNA) can provide therapeutically […]
This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.
Otherwise, you will be redirected to the institutional part of this website.
Thank you for your understanding.